https://www.fiercepharma.com/ a feed of the latest articles on our website en https://www.fiercepharma.com/webinars/partnering-to-advance-drug-delivery-innovation In this webinar, which is a rebroadcast from the 2025 PODD Conference, business development and technology assessment professionals actively involved in the scouting and evaluating of novel delivery technologies, discuss the constantly evolving topic of partnering.  Feb 26, 2026 8:07pm FiercePharma Staff https://www.fiercepharma.com/e3ce8286-3c13-4901-a818-9d6d897600e3 https://www.fiercepharma.com/manufacturing/forma-life-sciences-launches-cdmo-oral-solid-dosage-focus Forma Life Sciences, which inherited BioDuro’s California operations earlier this year, officially launched as a CDMO with a focus on oral solid dosage drugs this week. Mar 5, 2026 8:14am Joseph Keenan https://www.fiercepharma.com/2099871a-6e87-4aee-a38c-71b2db365d46 https://www.fiercepharma.com/pharma/fda-gives-glenmark-thumbs-first-true-generic-version-gsks-flovent The FDA has approved the first true generic version of GSK's asthma inhaler Flovent, signing off on Glenmark's fluticasone propionate inhalation aerosol. For more than two years, Prasco Laboratories has sold an "authorized generic" version of the treatment. Mar 5, 2026 11:15am Kevin Dunleavy https://www.fiercepharma.com/d8cbab53-c51d-4a63-a90f-821d6b852f89 https://www.fiercepharma.com/pharma/after-generic-defense-fails-merck-kgaa-expects-no-us-mavenclad-sales-after-march After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S. generics to its multiple sclerosis blockbuster Mavenclad. Mar 5, 2026 11:12am Fraiser Kansteiner https://www.fiercepharma.com/83f1b193-54d1-4909-8806-6cbd040456f5 https://www.fiercepharma.com/pharma/galderma-doubles-nemluvio-peak-sales-projection-4b-after-strong-atopic-dermatitis-launch Galderma has doubled its peak annual sales estimate for Nemluvio (nemolizumab) to more than $4 billion, following what CEO Flemming Ørnskov described as an “outstanding launch trajectory” for the Dupixent competitor in its first full year on the market. Mar 5, 2026 10:53am Angus Liu https://www.fiercepharma.com/a5313b8c-73fb-4b39-adac-598434472d3f https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026 In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. Jan 2, 2026 8:07am Angus Liu, Eric Sagonowsky, Fraiser Kansteiner, Kevin Dunleavy, Zoey Becker https://www.fiercepharma.com/39cf200b-2bd0-4cd5-889a-1c71e8f5c4fd https://www.fiercepharma.com/marketing/leo-roars-netflix-dtc-campaign-new-hand-eczema-cream-anzupgo Leo Pharma has decided “It’s GO time” for the launch of its JAK inhibitor cream Anzupgo. Having built its growth plans on the recently approved medicine, the Danish drugmaker is running a direct-to-consumer campaign, including an ad on streaming services. Mar 5, 2026 10:04am Nick Paul Taylor https://www.fiercepharma.com/38d6fcb9-238d-41d8-afae-79ff13aa3b3f https://www.fiercepharma.com/payers/eli-lilly-launches-its-direct-employer-platform-obesity-drugs Eli Lilly has officially launched Employer Connect, its direct-to-employer platform for its obesity medications, after teasing the rollout late last year. Mar 4, 2026 5:02pm Paige Minemyer https://www.fiercepharma.com/d1997ebf-677e-44a4-931c-478f7edff042 https://www.fiercepharma.com/marketing/collegium-enrolls-paris-hilton-jornay-pm-push-encouraging-adhd-community-embrace-your Collegium Pharmaceutical has tapped an appropriately glitzy star as the face of a new campaign spotlighting the bright side of life with attention-deficit/hyperactivity disorder. Mar 4, 2026 3:06pm Andrea Park https://www.fiercepharma.com/72d538dc-2052-4e0c-9986-2b32f974e904 https://www.fiercepharma.com/pharma/fda-answers-vandas-years-long-call-formal-hearing-sleep-drug-hetlioz-twice-rejected-jet-lag The company has been pressing the FDA to hold a formal hearing on its proposed jet lag label expansion for Hetlioz since it was first snubbed way back in 2019. Mar 4, 2026 2:42pm Zoey Becker https://www.fiercepharma.com/837581da-d41c-4d25-97a7-0d4b899fa773 https://www.fiercepharma.com/manufacturing/crdmo-bioduro-enters-taiwan-joint-venture-adding-taipei-commercial-api-plant BioDuro, headquartered in California, has set up a new joint venture with Taiwan drug ingredients manufacturer, Cenra API Solutions. The new enterprise will see Cenra’s commercial-scale facility in Taipei folded into BioDuro’s production network. Mar 4, 2026 2:47pm Fraiser Kansteiner https://www.fiercepharma.com/12ba360a-d9a6-4b83-8e8a-0005831959e2 https://www.fiercepharma.com/pharma/bayer-looking-one-more-year-resilience-growth-kicks-behind-nubeqa-kerendia The primary growth drivers in Bayer’s pharma sector—Nubeqa and Kerendia—are performing even better than the company anticipated and their momentum is expected to continue in 2026. But that won’t lead to growth of Bayer’s pharma business overall this year as two contraction drivers—Xarelto and Eylea—are working in the opposite direction. Mar 4, 2026 11:08am Kevin Dunleavy https://www.fiercepharma.com/a8cc9b11-56a0-42ea-a3b1-b45e7d3eb77e https://www.fiercepharma.com/marketing/novo-lands-another-fda-untitled-letter-time-apple-inspired-ozempic-ad Not long after Novo Nordisk received an untitled letter from the FDA disputing certain elements of the first TV spot for its Wegovy pill, another of the Danish drugmaker’s GLP-1 ads is in the regulator’s crosshairs. Mar 4, 2026 10:52am Andrea Park https://www.fiercepharma.com/9ed7936f-7498-4a21-b734-0267743549d0 https://www.fiercepharma.com/pharma/moderna-fronts-950m-more-potentially-line-settle-yearslong-covid-patent-litigation-genevant Moderna will pay $950 million upfront—and no future royalties—to settle patent litigation over its mRNA-based vaccine Spikevax. The case was brought by Roivant subsidiary Genevant and infectious disease biotech Arbutus back in 2022. Mar 4, 2026 10:06am Fraiser Kansteiner https://www.fiercepharma.com/c322460c-d2ec-4354-8a53-3d67e97300d0 https://www.fiercepharma.com/pharma/fda-ramps-crackdown-glp-1-drug-compounders-fresh-batch-30-warning-letters In the letters sent to 30 different telehealth companies that market compounded versions of GLP-1 drugs, the agency threatened "legal action without further notice." Mar 3, 2026 5:41pm Zoey Becker https://www.fiercepharma.com/29a7e3f8-a3ec-4fa4-aa65-85926104b717 https://www.fiercepharma.com/marketing/rising-stars-boehringers-chris-kraemer-power-patient-impact In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Kraemer discussed how patients inspire his work, his advice for industry veterans and how he unwinds on the fairway. Mar 3, 2026 3:06pm Natalie Missakian https://www.fiercepharma.com/6eb9caff-3be2-403b-be78-9f27bb94088f https://www.fiercepharma.com/marketing/danish-agency-noa-health-names-new-ceo-drive-global-expansion NoA Health has appointed Louisa Lee as CEO, putting the former Novo Nordisk and Pfizer employee at the head of the creative agency’s push to take its business global. Mar 4, 2026 2:36am Nick Paul Taylor https://www.fiercepharma.com/afa017ba-b5c7-401e-87d9-8097daf63ee7 https://www.fiercepharma.com/pharma/sanofi-strikes-15b-global-licensing-deal-sino-biopharm-first-class-jak-asset Sanofi is betting $1.53 billion on a novel drug from Sino Biopharmaceutical, securing global rights to a first-in-class JAK/ROCK inhibitor that could play a double role in the French pharma’s hematology and immunology pipeline. Mar 3, 2026 11:57pm Angus Liu https://www.fiercepharma.com/3e3981e6-8f88-4443-8d43-71e8abea37b8 https://www.fiercepharma.com/marketing/guardant-picks-patrick-dempsey-colorectal-cancer-blood-test-awareness Dr. McDreamy has signed onto yet another cancer awareness initiative. “Grey’s Anatomy” star Patrick Dempsey, who has worked with Amgen since 2007 and joined forces with Pfizer in 2024, is now collaborating with cancer test maker Guardant Health. Mar 3, 2026 12:18pm Andrea Park https://www.fiercepharma.com/a733af68-96c6-42ac-a788-1b95bdebbfd5 https://www.fiercepharma.com/pharma/pfizer-ceo-bourla-cber-chief-prasad-we-have-problem-leadership-cber Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp criticism of the FDA’s Vinay Prasad, M.D., and his performance as the chief of the Center for Biologics Evaluation and Research, which regulates vaccines in the U.S. Mar 3, 2026 4:37pm Kevin Dunleavy https://www.fiercepharma.com/80a11131-6901-49e3-a321-c01d3fb17e5e https://www.fiercepharma.com/pharma/irelands-biopharma-foothold-stands-firm-amid-tariff-tinged-us-production-blitz Amid an influx of U.S. investments, geopolitical uncertainties support the need for manufacturing projects in other regions, IDA Ireland's Rory Mullen told Fierce. Mar 3, 2026 4:31pm Fraiser Kansteiner https://www.fiercepharma.com/b8d299c6-0708-44dc-a6ed-11bdec91003d https://www.fiercepharma.com/pharma/acadia-seeks-chmp-re-examination-rett-syndrome-med-daybue-following-eu-rejection The European Medicines Agency's Committee for Medicinal Products for Human Use turned down Acadia's Daybue application for Rett syndrome in late February based on concerns with the company's pivotal trial. Mar 3, 2026 10:57am Zoey Becker https://www.fiercepharma.com/6b3fd06c-bb51-4771-be04-ab514070c263 https://www.fiercepharma.com/pharma/fda-crl-reveal-critical-errors-astrazeneca-saphnelo-gsk-exdensur-rejection The FDA is providing more insight into the rejections it recently handed two pharma giants, publishing the complete response letters (CRLs) sent to AstraZeneca and GSK that highlight shortfalls in the data included in their application packages. Mar 3, 2026 10:50am Angus Liu https://www.fiercepharma.com/864b1190-3a84-41bb-a253-aca1a922f915 https://www.fiercepharma.com/biotech/disc-lays-20-employees-it-steadies-ship-after-fda-rejection-rare-disease-drug Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate. Mar 3, 2026 9:59am James Waldron https://www.fiercepharma.com/2a2aff6c-444d-4678-8ef3-3c561e0e2b1a https://www.fiercepharma.com/pharma/novo-plugs-500m-ireland-plant-produce-wegovy-pill-markets-outside-us Novo will invest 432 million euros ($501 million) to add a new tableting plant at its facility in Athlone, Ireland, the company said in a March 2 press release. The expansion will equip the Athlone site with significant additional capacity for Novo’s suite of current and future GLP-1 medicines. Mar 3, 2026 9:25am Fraiser Kansteiner https://www.fiercepharma.com/3c5994c1-3ef6-4395-bd07-f5a6cbb65e1c